Seek Returns

BMRN vs. PCVX: BioMarin Pharmaceutical vs. Vaxcyte Stock Comparison

How do BioMarin Pharmaceutical (BMRN) and Vaxcyte (PCVX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

BioMarin Pharmaceutical (BMRN) and Vaxcyte (PCVX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

BioMarin Pharmaceutical (BMRN) has more than two decades of public-market history since July 26, 1999, whereas Vaxcyte (PCVX) listed on June 12, 2020 and has a much shorter record to draw on.

Company profile comparison for BioMarin Pharmaceutical (BMRN) and Vaxcyte (PCVX)
Profile ItemBMRNPCVX
NameBioMarin Pharmaceutical Inc.Vaxcyte Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization10.85 billion USD10.11 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJuly 26, 1999June 12, 2020
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

BMRN
PCVX
GSPC
Loading price history…
BioMarin Pharmaceutical (BMRN) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for BioMarin Pharmaceutical (BMRN) and Vaxcyte (PCVX). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for BioMarin Pharmaceutical (BMRN) and Vaxcyte (PCVX). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for BioMarin Pharmaceutical (BMRN) and Vaxcyte (PCVX)
MetricBMRNPCVX
Total Return (1Y)8.82%59.00%
Total Return (3Y, Annualized)-12.54%11.29%
Total Return (5Y, Annualized)-7.51%21.60%

Risk Profile

Drawdown History

BMRN
PCVX
GSPC
Loading price history…
BioMarin Pharmaceutical (BMRN) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for BioMarin Pharmaceutical (BMRN) and Vaxcyte (PCVX). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for BioMarin Pharmaceutical (BMRN) and Vaxcyte (PCVX)
MetricBMRNPCVX
Volatility (1Y, Annualized)35.50%56.01%
Beta (5Y)0.241.26
Max Drawdown (5Y)-57.64%-76.22%
Avg. Volume (3M)2.28M2.12M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BMRN and PCVX are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for BioMarin Pharmaceutical (BMRN) and Vaxcyte (PCVX)
MetricBMRNPCVX
Sharpe Ratio (1Y)0.130.98
Sortino Ratio (1Y)0.231.76

Profitability

ROE (TTM)

Both BioMarin Pharmaceutical (BMRN) at -0.31% and Vaxcyte (PCVX) at -42.68% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.31%

Max
109.18%
Q3
6.23%
BMRN
-0.31%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-42.68%

Max
109.18%
Q3
6.23%
Median
-26.66%
PCVX
-42.68%
Q1
-64.05%
Min
-167.77%
Loading chart…
BioMarin Pharmaceutical (BMRN) vs. Vaxcyte (PCVX): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

BioMarin Pharmaceutical (BMRN) reports a negative net margin of -0.52%, usually indicating a net loss over the period. Meanwhile Vaxcyte (PCVX) reports 0.00%, ranking against industry peers normally.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.52%

Max
18.05%
Q3
4.78%
Median
0.00%
BMRN
-0.52%
Q1
-4.14%
Min
-17.05%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
PCVX
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
BioMarin Pharmaceutical (BMRN) vs. Vaxcyte (PCVX): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

BioMarin Pharmaceutical (BMRN) at 26.58% operates in the top operating margin quartile, ahead of Vaxcyte (PCVX) at 0.00%, which runs around its industry’s norm.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.58%

Max
83.12%
BMRN
26.58%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
83.12%
Q3
14.77%
PCVX
0.00%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
BioMarin Pharmaceutical (BMRN) vs. Vaxcyte (PCVX): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for BioMarin Pharmaceutical (BMRN) and Vaxcyte (PCVX)
MetricBMRNPCVX
ROE (TTM)-0.31%-42.68%
ROA (TTM)3.89%-24.98%
Net Margin (TTM)-0.52%0.00%
Operating Margin (TTM)26.58%0.00%
Gross Margin (TTM)53.21%0.00%

Growth

Revenue Growth

Only one side can be read here: BioMarin Pharmaceutical (BMRN) reports revenue growth of 12.87%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Loading chart…
BioMarin Pharmaceutical (BMRN) vs. Vaxcyte (PCVX): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: BioMarin Pharmaceutical (BMRN) reports EPS growth of -18.55%, ranked against its industry; Vaxcyte (PCVX) has no EPS growth figure this period.

Loading chart…
BioMarin Pharmaceutical (BMRN) vs. Vaxcyte (PCVX): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for BioMarin Pharmaceutical (BMRN) and Vaxcyte (PCVX)
MetricBMRNPCVX
Revenue Growth (YoY)12.87%--
Revenue Growth (3Y CAGR)15.40%--
EPS Growth (YoY)-18.55%--
EPS Growth (3Y CAGR)33.89%--

Financial Strength

Current Ratio (MRQ)

Vaxcyte (PCVX) at 4.56 keeps current ratio within its industry’s typical mid-range, while BioMarin Pharmaceutical (BMRN) at 2.44 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BMRN.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.44

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
BMRN
2.44
Min
0.10

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.56

Max
25.13
Q3
12.13
Median
5.52
PCVX
4.56
Q1
2.47
Min
0.10
Loading chart…
BioMarin Pharmaceutical (BMRN) vs. Vaxcyte (PCVX): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Vaxcyte (PCVX) at 0.09 carries an industry-typical debt-to-equity mix, while BioMarin Pharmaceutical (BMRN) at 0.67 uses more debt funding than most peers.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.67

Max
1.42
BMRN
0.67
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
PCVX
0.09
Q1
0.02
Min
0.00
Loading chart…
BioMarin Pharmaceutical (BMRN) vs. Vaxcyte (PCVX): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for BioMarin Pharmaceutical (BMRN) and Vaxcyte (PCVX)
MetricBMRNPCVX
Current Ratio (MRQ)2.444.56
Debt / Equity (MRQ)0.670.09
Net Debt / EBITDA4.04--

Dividends

Dividend Yield (TTM)

Neither BioMarin Pharmaceutical (BMRN) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BMRN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
BioMarin Pharmaceutical (BMRN) vs. Vaxcyte (PCVX): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither BioMarin Pharmaceutical (BMRN) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BMRN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
BioMarin Pharmaceutical (BMRN) vs. Vaxcyte (PCVX): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for BioMarin Pharmaceutical (BMRN) and Vaxcyte (PCVX)
MetricBMRNPCVX
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Neither BioMarin Pharmaceutical (BMRN) nor Vaxcyte (PCVX) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
BMRN
--

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
PCVX
--
Loading chart…
BioMarin Pharmaceutical (BMRN) vs. Vaxcyte (PCVX): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

A sales-based read is only available for BioMarin Pharmaceutical (BMRN), whose P/S ratio of 2.97 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.97

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
BMRN
2.97
Min
0.01

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
PCVX
--
Loading chart…
BioMarin Pharmaceutical (BMRN) vs. Vaxcyte (PCVX): PCVX does not report P/S ratio, so it has no value marker; BMRN is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

On P/B ratio, both BioMarin Pharmaceutical (BMRN) at 1.73 and Vaxcyte (PCVX) at 3.83 are valued close to their industries’ norm against book — neither stands out from peers.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.73

Max
13.53
Q3
6.54
Median
3.25
BMRN
1.73
Q1
1.69
Min
-5.59

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.83

Max
13.53
Q3
6.54
PCVX
3.83
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
BioMarin Pharmaceutical (BMRN) vs. Vaxcyte (PCVX): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for BioMarin Pharmaceutical (BMRN) and Vaxcyte (PCVX)
MetricBMRNPCVX
P/E Ratio (TTM)----
P/S Ratio (TTM)2.97--
P/B Ratio (MRQ)1.733.83
Free Cash Flow Yield (TTM)-0.15%-5.24%